

**Review Article**  
**A Review On  
Thiazole As  
Anticancer Agents**

**Harpreet Kaur\*, Anjali Goyal**

Department of Pharmaceutical Chemistry,  
A.S.B.S.J.S.M. College of Pharmacy,  
Bela, 140111(Punjab), India

Date Received: 16<sup>th</sup> April 2018; Date accepted: 5<sup>th</sup>  
May 2018; Date Published: 6<sup>th</sup> May 2018

**Abstract**

A study on heterocyclic compounds is of great interest in pharmaceutical area. This has catalyzed the discovery and development of much new heterocyclic chemistry and methods. In fact, one of the reasons for the wide spread use of heterocyclic compounds is that their structures can be suitably manipulated to achieve a required modification in function. Literature survey shows that the modifications of thiazole ring have highly effective to improve potency and lesser toxicity. The present review shows the important biological activity (Anticancer Activity) possesses by thiazole.

**Keywords:** Thiazole derivatives, Anticancer activity.

**INTRODUCTION**

Now a days, in the pharmaceutical area study on heterocyclic compounds is of great interest. The discovery and development of much new heterocyclic chemistry and methods is catalysed by this study. The main reasons for the wide spread use of heterocyclic compounds is that the structures of heterocyclic compounds can be suitably manipulated to achieve a required modification in functions. Knowledge of heterocyclic chemistry is benefit in biosynthesis and drug metabolism. So, pharmaceutical and agrochemical industries have made rapid and significant progresses to quench the quest of organic chemists in discover-

ing and developing suitable heterocyclic compounds for the benefit of mankind. Thus, heterocyclic chemistry attracts scientists to working in the area of natural products as well as synthetic organic chemistry. The reason for the upsurge in the interest and development of these heterocyclic compounds is due to their pesticidal, potential chemotherapeutic, fungicidal and antiviral properties. A number of heterocyclic derivatives containing nitrogen have been used as versatile scaffolds in drug development.

Thiazoles are the class of organic compounds related to azoles containing thiazole as a functional group. Thiazoles are aromatic, heterocyclic organic compound which have a five-membered ring structure with molecular formula  $C_3H_3NS$ [1]. As the heterocyclic compounds are interest for its theoretical implications due to its synthetic procedure and physiological and industrial significance[2]. Thiazole and its derivatives are the most utilized heterocycles. Thiazole ring system plays an important role in the drug market with a wide spectrum of activity such as antibacterial, antifungal and antiviral [3]. Natural products having thiazole ring are known for their antibiotic and antifungal activities [4]. Marine products having thiazole ring exhibit anti-neoplastic, antifungal and inflammatory activity [5]. Naturally thiazole ring is found in essential vitamin B<sub>1</sub>, bacitracin, and penicillins. Thiamine is a water soluble vitamin that helps the body release energy from carbohydrates during metabolism. It also helps in the normal functioning of the nervous system by its role in the synthesis of acetylcholine, a neurotransmitter. Thiamine is found mostly in pasta and breads made from refined flours. It is also found in ready-to-eat cereals and in navy and kidney beans. Other thiazole compounds include rhodanine and the dye rhodanine red derived from it, and the yellow dye primuline. Synthetic drugs belonging to the thiazole family include sulfathiazole, sulfasuxidine, and thiazolsulfone (Promizole). 2-Mercapto- benzothiazole (Mertax) is a thiazole derivative used for accelerating the vulcanization of rubber.

Thiazole derivatives were found to possess anti-convulsant, antimicrobial, anti-inflammatory, anticancer, anti-HIV, antidiabetic, anti-alzheimer,

antihypertensive and antioxidant activities. Due to its potent and significant biological activities it has great pharmaceutical importance; hence, synthesis of this compound is of considerable interest[6,7].

- 4- Thiazolidone derivatives have found to show a very good antifungal activity.
- (1, 3 benzothiazol-2yl) amino 9-(10H) acridinone derivatives[8] have found to possess antileishmanial activity.
- 4-Substituted Methoxybenzoyl-aryl-thiazole has been found to possess a very good anti-cancer activity.

They have been studied extensively because of their ready accessibility, diverse chemical reactivity and broad spectrum of biological activity [9].

Recently the applications of thiazoles were found in drug development for the treatment of allergies, hypertension, inflammation, schizophrenia, bacterial, HIV infections[10], hypnotics[11] and more recently for the treatment of pain[12], as fibrinogen receptor antagonists with antithrombotic activity[13] and as new inhibitors of bacterial DNA gyrase B[14]. Thiazoles containing N=C=S moiety has been employed as anti-psychotic and anti-bacterial activity.

The substituted thiazoles compounds have number of characteristics pharmacological features such as:

1. Relative stability
2. Ease of starting material.
3. Built biocidal unit.
4. Enhanced lipid solubility with hydrophilicity.
5. Easy metabolism of compounds.

## CHEMISTRY

Thiazole is a heterocyclic compound containing both a nitrogen and sulphur atom as part of the aromatic five-member ring. Thiazole and related compounds are 1,3-azoles. They are isomeric with the 1,2-azoles **Figure 1**, known as isothiazole. The numbering system is shown below for naming derivatives of thiazoles[15].

## STRUCTURE ACTIVITY RELATIONSHIP

From the literature review the structural activity relationship of the thiazole ring can be summarized as follows **Figure 2**[16].

- ❖ The ester group at position 2 of thiazole ring is necessary to have higher antitumor activity than the acetyl and N-phenyl carboxamide groups.
- ❖ The presence of chlorine group at the position 2, 4 or 4 in the aryl moiety had high cytotoxic activity than halogen at position 3.
- ❖ 4-Substituted Methoxybenzoyl-aryl-thiazole has been found to possess a very good anti-cancer activity.
- ❖ Methyl substituted benzyl group at the 2<sup>nd</sup> position of the thiazole ring is more potent than the phenyl substitution.
- ❖ m-Phenylsulphanamido group at the 4<sup>th</sup> position shows antibacterial activity.
- ❖ The compounds with methyl substitution in the 5<sup>th</sup> position of the thiazole ring were found to be less active against M. Tuberculosis than the compound with no substitution in the 5<sup>th</sup> position.
- ❖ Different thiazole molecules when fused with pyrazole ring containing heterocycles presents antibacterial activity.
- ❖ Aryl amino thiazoles were found to possess effective antibacterial and anti-inflammatory activity.
- ❖ Potent derivatives have highly electronegative part of sulfhydryl group, specifically Schiff bases, probably due to their ability to increase the penetration in the bacterial cell. Cyano group has no role.
- ❖ Optimization of sulfhydryl group reveals loss of activity.
- ❖ Free amino group have open area for the further modification.

## BIOLOGICAL ACTIVITY

Thiazoles and fused thiazole derivatives are known to possess several biological activities including anticancer activity[17,19]. There are a variety of mechanisms for the antitumor action of thiazole and fused thiazole derivatives, acting on cancer biotargets, such as tumor necrosis factor TNF-  $\alpha$ [20], inosine monophosphate dehydrogenase (IMPDH) [21] and apoptosis inducers [22]. Tiazofurin **Figure 3**[23] the synthetic nucleoside analogue, is a potent inhibitor of inosine monophosphate dehydrogenase (IMPDH). Inhibition of this enzyme results in a decrease in gu-

anosine triphosphate (GTP) and deoxyguanosine triphosphate (dGTP) biosynthesis, producing inhibition of tumor cell proliferation.

Tiazofurin is a high-priority candidate for clinical trials with potential importance for treatment of lung tumours, metastases and acute myelogenous leukaemia[24,26]. To improve its biological properties, many analogues had been prepared, including a number of those with variations in the furanose ring for example compoundsFigure 4[27-29].

Some nicotinamide adenine dinucleotide (NAD) analogues were modified at the nicotinamide moiety and were identified as active antitumor and antiviral. For example thiazole-4-carboxamide adenine dinucleotide analogues were prepared as potential selective human (IMPDH) inhibitorsFigure 5[30].

Epothilones,Figure 6 is a recent class of natural products which have been reported to exhibit extraordinarily potent cytotoxicity in a broad range of human cancer cell lines, in addition epothilones are known to induce mitotic arrest at the G2/M transition leading to apoptotic cell death. Epothilones are apoptosis inducers through one of two pathways, namely a receptormediated and a non receptor-mediated or chemical-induced pathway [31,32]. Thus epothilones, have much greater activity against multi-drug resistant cell lines[33].

The position of the thiazole-containing side chain of epothilones was investigated. Among a tested series of hybrid compounds the one containing thiazole side chain at C<sub>15</sub> (MSt-2) showed the maximum potency to induce apoptosis, while another containing thiazole side chain at C<sub>3</sub> (MSt-6) was less potentFigure 7[34]. Thus it was reported that the 16membered trilactone core structure with a thiazole-containing side chain of epothilones were promising apoptosis inducers[35].

## BIOLOGICAL ACTIVITY REVIEW

**A. Grozavet al.**, synthesized 2-(2-((1H-indol-5yl)methylene)-hydrazinyl)-thiazole derivatives-Figure 8. These derivatives evaluated for their in vitro cytotoxicity on two carcinoma cell lines; human ovarian cancer cells (A2780) and human cervical cancer cells (HeLa). Compounds **1a** and **1c** had a good inhibition on both A2780 and HeLa while derivative **1e** has been active only on HeLa cell lines [36].

**B. Parrinoet al.**, synthesized new series of thiazolenortopsentin analoguesFigure 9. The antiproliferative activity of the new derivatives was tested against different human tumor cell lines of the NCI full panel of approximately 60 human cancer cell lines derived from 9 human cancer cell types that have been grouped into disease subpanels including leukemia, non-small cell lung, colon, central nervous system, melanoma, ovarian, renal, prostate, and breast tumor cell lines. The compounds **2a**, showed antiproliferative activity in the micromolar to nanomolar range (GI<sub>50</sub> 0.03-98.0 μM). Compounds **2a** and **2o** were active against the total number of cell lines investigated, whereas compounds **2m** and **2n** were cytotoxic against a very high percentage of the tested cell lines (96% and 93% respectively) [37].

**Sadashivet al.**, synthesized a series of 2,4-disubstituted-1,3-thiazoles linked with pyrazoline scaffoldsFigure 10. The compounds were evaluated for their anticancer activity against A549 and MCF-7 human cancer cell lines and in vitro antimicrobial activity against pathogenic microbial strains. The compounds **3a,3c** and **3d**, exhibited better activity than standard drug Cisplatin[38].

**S. P. Shaiketal.**, synthesized a new class of 1,2,3-triazolo linked benzo[d]imidazo[2,1-b]thiazole conjugatesFigure 11 and evaluated for their cytotoxic activity. Among them, conjugates **4b** and **4d** showed significant cytotoxic activity against the human breast cancer cell line (MCF-7) [39].

**G. T. Zitouniet al.**, synthesized new bis-thiazole derivativesFigure 12 and investigated for their cytotoxic effects on A549 human lung adenocarcinoma, C6 rat glioma, 5RP7 H-ras oncogene transformed rat embryo fibroblast and NIH/3T3 mouse embryonic fibroblast cell lines and DNA synthesis inhibitory effects. The inhibitory effects of these compounds on AChE and BuChE were also evaluated. Among these compounds, compound **5e** was found to be the most promising anticancer agent due to its remarkable antiproliferative effects on A549 and C6 cell lines and low cytotoxicity against NIH/3T3 cells[40].

**G. Y. Yeapet al.**, synthesized a new hydroxybenzene modified thiazole-azo derivativeFigure 13 and its chemosensing towards heavy metal ions (Na<sup>+</sup>, Al<sup>3+</sup>, K<sup>+</sup>, Ca<sup>2+</sup>, Mn<sup>2+</sup>, Fe<sup>2+</sup>, Ni<sup>2+</sup>, Cu<sup>2+</sup>, Zn<sup>2+</sup>, Ag<sup>+</sup>, Cd<sup>2+</sup>, Hg<sup>2+</sup> and Pb<sup>2+</sup>) was characterized by UV-vis spectroscopy[41].

**F. I. Hamedet al.**, synthesized and characterized

a series of new heterocyclic compounds with the thiazole nucleus **Figure 14**. The 2-amino-4-(4-chlorophenyl)-6-(4-phenylthiazol-2-yl)-4H-pyran-3,5-dicarbonitrile **7b** showed the maximum cytotoxicity among the synthesized compounds towards the six cancer cell lines [42].

**T. A. R. Santos et al.**, evaluated 1,3-thiazole and thiosemicarbazone compounds **Figure 15** for Antitumor and immunomodulatory activities. The compounds **8a**, **8b**, and **8c** are most potent anticancer and immunomodulatory agent [43].

**S. Mirza et al.**, synthesized substituted aryl thiazoles **Figure 16** and their in vitro cytotoxicity was evaluated against four cancer cell lines, MCF-7 (ER+ve breast), MDA-MB-231 (ER-ve breast), HCT116 (colorectal) and HeLa (cervical). Among them, compounds **9a-9e** were found to be toxic to all four cancer cell lines [44].

**W. X. Cai et al.**, synthesized a series of novel 2-phenyl-4-trifluoromethyl thiazole-5-carboxamide derivatives **Figure 17** and evaluated for their anticancer activity against A-549, Bel7402, and HCT-8 cell lines. Compound **11a** (48%) and **11b** (40%), which is a little lower than that of control, while some of them exhibited low activity against A-549. Furthermore, compound **10a** and **10b** can increase the A-549 cell growth. All the title compounds exhibited no inhibition or low inhibitor effect against Bel7402 and HCT-8. Compound **10b** (40%) displayed moderate inhibitory against HCT-8 [45].

**S. M. Gomhaet et al.**, synthesized new thiazole derivatives **Figure 18**. Compounds **12a**, **12b** and **12c** may have significant and promising anticancer efficiency for hepatocellular carcinoma with low IC<sub>50</sub>, 0.5, 0.02, 0.52, 0.03, and 0.84, 0.04 μM, respectively [46].

**R. Ali et al.**, synthesized a series of imidazo[2,1-b]thiazoles bearing pyrazole moieties **Figure 19** and evaluated for anticancer activity. The in vitro anticancer evaluation revealed that compounds **13a**, **13b**, **13c** exhibited increased potency towards CNS SNB-75 and Renal UO-31 cancer cell lines [47].

**S. Koppireddi et al.**, synthesized a series of new 3,6-diphenylimidazo[2,1-b]thiazole derivatives **Figure 20** and evaluated for their anticancer activity. Among the all synthesized compounds, **14c** were most potent anti-proliferative activity against HeLa, MDA-MB-231, A549 and THP1 human cancer cell lines [48].

**S. A. F. Rostomet et al.**, synthesized novel bifunctional ethyl 2-amino-4-methylthiazole-5-carboxylate derivatives **Figure 21**. Five cell lines namely; the non-small cell lung cancer Hop-92, NCI-H522, ovarian cancer IGROV1, colon cancer HCC-2998 and melanoma SK-MEL-2 exhibited remarkable sensitivity against most of the tested compounds. Compound **15** proved to possess a broad spectrum of anticancer activity against 29 of the tested 60 subpanel tumor cell lines [49].

**B. L. Zhang et al.**, synthesized a series of steroidal[17,16-d]thiazole, steroidal[1,2-b]pyridine and steroidal[17,16-d]thiazole[2,1-b]imidazo products **Figure 22**. These compounds were evaluated for their anti-proliferation activity in vitro against EC109, EC9706 and MGC803 cell lines. Bioactivities test results showed that compound **16** series have a relatively good activity against the three cell lines, especially EC109 cell line [50].

**M. S. A. Saadi et al.**, synthesized and evaluated two series of 2,4,5-polysubstituted thiazoles comprising the acid hydrazide functionality and some derived pharmacophores known to contribute to various chemotherapeutic activities **Figure 23**. Compounds were selected and tested for their preliminary in-vitro anticancer activity according to the current one-dose protocol of the NCI. Three cell lines, non-small cell lung cancer Hop-92, ovarian cancer IGROV1, and melanoma SK-MEL-2, exhibited some sensitivity against most of the tested compounds. Compound **17** proved to be the most active anticancer member with a broad spectrum of activity against most of the tested subpanel tumor cell lines [51].


**K. M. Dawood et al.**, synthesized 2-(4-(pyrazol-4-yl)thiazol-2-ylimino)-1,3,4-thiadiazole derivatives **Figure 24**. Compounds **18a-c**, and **19a-b** were tested for their in-vitro antitumor activity against human hepatocellular carcinoma cell (HepG2), human breast cancer cells (MCF-7) and human lung cancer cells (A549) [52].

## REFERENCES

1. Siddiqui N, Kumar SA, Ahsan W, Azad B. Diverse biological activity of thiazoles. *IJDDR* 2011;3:55-67.
2. Jagdale BS, Adole VA. Facile synthesis of 2-amino thiazole derivatives and their biological evaluation. *Int. J. of Pharm. Research Scholars* 2015;4:1-3.
3. Dondoni A, Merino P. *Comprehensive Heterocyclic Chemistry II* 1996;3:467.
4. Shao J, Panek JS. *Organic Letters* 2004;6:3083.

5. Bhalla M, Hitkari A, Gujrati VR, Bhalla TN, Shankar K. Synthesis of new 1,2,4-triazolo 3,4-b,3,4- thiazidines and study of their ant candida and cytotoxic activity . *Eur J Med Chem* 1994;29:713.
6. Singh I, Kaur H, Kumar S, Lata S, Kumar A. Synthesis and antibacterial activity of 3-chloro 4- (substitutedphenyl) azetidinyloxy/thiazolidinonyl-4- (3acetanilido) oxa/thiazoles. *Int J PharmaSci and Res* 2010;1:148-168.
7. Cai W, Liu A, Li Z, Dong W, Liu X, Sun N. Synthesis and Anticancer Activity of Novel Thiazole-5-Carboxamide Derivatives. *ApplSci* 2016;6:1-8.
8. Pucci JM, Bronson JJ. Antimicrobial Evaluation of Nocanthiacins, a Thiazole peptide class. *Antimicrobial agents Chemotherapy* 2004;48:3697-3701.
9. Siddiqui N, Arya SK, Ahsanb W, Azad B. Diverse biological activities of Thiazoles: A Retrospect. *Int J of Drug Dev& Res* 2011;3:156-164.
10. Chou TC, Zhang XG, Balog A, Su DU, Meng D, Savin K, Bertino JR, Danishefsky SJ. *Proc Nat AcadSci USA* 1998;95:9642-9647.
11. Chou TC, Zhang XG, Harris CR, Kuduk SD, Balog A, Savin K, Danishefsky SJ. *Proc Nat AcadSci* 1998;95:15798-15802.
12. Hofle G, Glaser N, Leibold T, Sefleow M. *Pure ApplChem* 1999;71:2019-2024.
13. Humphries TJ, Merritt GJ, Aliment GJ. *PharmacolTher* 1999;3:18–26.
14. Eicher T, Hauptmann S. *The Chemistry of Heterocycles*. Ch:5.29. 2005;149-154.
15. Kotadiya M. *International Journal Of Advancement In Engineering Technology, Management and Applied Science (IJAET-MAS)* 2017;4:24-44.
16. Zagade AA, Senthilkumar GP. *Der Pharm-Chemica* 2011;3:523-537.
17. Lesyk R, Vladzimirska O, Holota S, Zaprutko L, Gzella A. *Eur J Med Chem* 2007;42:640-641.
18. Havrylyuk D, Zimenkovsky B, Vasylenko O, Zaprutko L, Gzella A, Lesyk R. *Eur J Med Chem* 2009;44:1396.
19. Kaminsky D, Zimenkovsky B, Lesyk R. *Eur J Med Chem* 2009;44:3627.
20. Carter PH, Scherle PA, Muckelbauer JA, Voss ME, Liu RQ, Thompson LA, Tebben AJ, Solomon KA, Lo YC. *Proc Natl AcadSci U.S.A* 2001;98:11879.
21. Franchetti P, Grifantini M. *Curr Med Chem* 1999;6:599.
22. Matsuya Y, Kawaguchi T, Ishihara K, Ahmed K, Zhao QL, Kondo T, Nemoto H. *Org. Lett* 2006;8:4609.
23. Srivastava PC, Pickering MV, Allen LB, Streeter DG, Campbell MT, Witkowski JT, R.W. Sidwell, R.K. Robins. *J. Med. Chem.* 1977;20:256.
24. Robins RK, Srivastava PC, Narayanan VL, Plowman L, Paull KD. *J. Med. Chem.* 1982;25:107.
25. Weber G, Shen F, Orban TI, Kokeny S, Olah E. *Adv. Enzyme Regul.* 2003;43:47.
26. Tricot GJ, Jayaram HN, Heerema N, Weber G, Hoffman R. *Cancer Res.* 1989;49:3696.
27. Merino P, Tejero T, Unzurrunzaga FJ, Franco S, Chiacchio U, Saita MG, Iannazzo D, Pipernoc A, Romeo G. *Tetrahedron: Asym.* 2005;16:3865.
28. Popsavin M, Spaic S, Svircev M, Kojic V, Bogdanovic G, Popsavina V. *Bioorg. Med. Chem. Lett.* 2006;16:5317.
29. Popsavin M, Spaic S, Svircev M, Kojic V, Bogdanovic G, Popsavina V. *Bioorg. Med. Chem. Lett.* 2007;17:4123.
30. Franchetti P, Cappellacci L, Pasqualini M, Petrelli R, Jayaprakasan V, Jayaram HN, Boyd DB, Jain MD, Grifantini M. *Bioorg. Med. Chem.* 2005;13:2045.
31. Wolff A, Technau A, Brandner G. *Int. J. Oncol.* 1997;11:123.
32. Ashkenazi S, Cleary TG. *J. Med. Microbiol.* 1990;32:255.
33. Sun XM, MacFarlane M, Zhuang J, Wolf BB, Green DR, Cohen GM. *J. Biol. Chem.* 1999;274:5053.
34. Bollag DM, McQueney PA, Zhu P, Hensens O, Koupal L, Liesch J, Goetz M, Lazoides E, Woods CM. *Cancer Res.* 1995;55:2325.
35. Ahmed K, Matsuya Y, Nemoto H, Faisal S, Zaidi H, Sugiyama T, Yoshihisa Y, Shimizu T, Kondo T. *Chem. Biol. Inter.* 2009;177:218.
36. Grozav A, Porumb ID, Gařina LI, Filip L, Hanganu D. Cytotoxicity and Antioxidant Potential of Novel 2-(2-((1H-indol-5yl)methylene)-hydrazinyl)-thiazole Derivatives. *Molecules.* 2017:1-12.
37. Parrino B, Attanzio A, Spano V, Cascioferro S, Montalbano A, Barraja P, Tesoriere L, Diana P, Cirrincione G, Carbone A. Synthesis, antitumor activity and CDK1 inhibition of new thiazolenortopsentinanalogues. *Eur J Med Chem.* 2017:1-12.

38. Sadashiva R, Naral D, Kudva J, Madan SK, Byrappa K, Mohammed RS, Kumsi M. Synthesis, structure characterization, in vitro and in silicobiological evaluation of a new series of thiazole nucleus integrated with pyrazoline scaffolds. *J Mole Stru.* 2017:1-20.
39. Shaik SP, Vishnuvardhan MVPS, Sultana F, SubbaRao AV, Bagul C, Bhattacharjee D, Kapure JS, Jain N, Kamal A. Design and synthesis of 1,2,3-triazolo linked benzo[d]imidazo[2,1-b]thiazole conjugates as tubulin polymerization inhibitors. *Bioorg& Med Chem* 2017;25:3285–3297.
40. Zitouni GT, Altntop MD, Ozdemir A, Kaplancıklı ZA, Çiftçi GA, Temel HE. Synthesis and Evaluation of Bis-thiazole Derivatives as New Anticancer Agents. *Eur J Med Chem* 2015:1-16.
41. Yeap GY, Hrishikesan E, Chan YH, Mahmood WAK. Synthesis and salient chemosensing properties of a new thiazole-azo derivative. *Tetrahedron* 2017:1-11.
42. Hamed FI, Mohamed AA, Abouzied AS. The Uses of 2-Amino-4-Phenylthiazole in the Synthesis of Coumarin, Pyran, Pyridine and Thiazole Derivatives with Antitumor Activities. *Open Acc Lib J* 2017:1-16.
43. Santosa TA, Silvaa AC, Silvab EB, Gomesb PATM, Espindolab JWP, Cardosob MVO, Moreirac DRM, Leiteb ACL, Pereiraa VRA. Antitumor and immunomodulatory activities of thiosemicarbazones and 1,3-Thiazoles in Jurkat and HT-29 cells. *Biomed Pharma* 2016;82:555-560.
44. Mirza S, Naqvi SA, Khan KM, Salar U, Choudharya MI. Facile Synthesis of Novel Substituted Aryl-ThiazoleAnalog via One-Pot Multicomponent Reaction as Potent Cytotoxic Agents against Cancer Cell lines. *BioorgChem* 2016:1-28.
45. Cai WX, Liu AL, Li ZM, Dong WL, Liu XH, Sun NB. Synthesis and Anticancer Activity of Novel Thiazole-5-Carboxamide Derivatives. *Molecules.* 2016:1-10.
46. Gomha SM, Salaheldin TA, Hassaneen HME, Aziz HMA, Khed MA. Synthesis, Characterization and Molecular Docking of Novel Bioactive Thiazolyl-Thiazole Derivatives as Promising Cytotoxic Antitumor Drug. *Molecules* 2015:1-17.
47. Ali AR, Bendary ER, Ghaly MA, Shehata IA. Synthesis, in vitro anticancer evaluation and in silico studies of novel imidazo[2,1-b]thiazole derivatives bearing pyrazole moieties. *Eur J Med Chem.* 2014;75:492-500.
48. Koppireddi S, Chilaka DRK, Avula S, Kom sani JR, Kotamraju S, Yadla R. Synthesis and anticancer evaluation of 3-aryl-6-phenylimidazo [2,1-b]thiazoles. *Bioorg& Med ChemLett.* 2014;24:5428–5431.
49. Rostoma SAF, Faidallah HM, Radwan MF, Badr MH. Bifunctional ethyl 2-amino-4-methylthiazole-5-carboxylate derivatives, Synthesis and in vitro biological evaluation as antimicrobial and anticancer agents. *Eur J Med Chem.* 2014;76:170-181.
50. Zhang BL, Song LX, Li YF, Li YL, Guo YZ, Zhang E, Liu HM. Synthesis and biological evaluation of dehydroepiandrosterone-fusedthiazole, imidazo[2,1-b]thiazole, pyridine steroidal analogues. *Steroids.* 2014;80:92–101.
51. Saadi MSA, Faidallah HM, Rostom SAF. Synthesis and Biological Evaluation of Some 2,4,5-Trisubstituted Thiazole Derivatives as Potential Antimicrobial and Anticancer Agents, *Arch.Pharm.Chem.Life Sci.* 2008:424–434.
52. Dawood KM, Eldebss TMA, El-Zahabi HSA, Yousef MH, Metz P. Synthesis of some new pyrazole-based 1,3-thiazoles and 1,3,4-thiadiazoles as anticancer agents. *Eur J Med Chem.* 2013:1-23.



ThiazoleIsothiazole (1,3-azole) (1,2-azole)

Figure 1






Figure 2



Tiazofurin

Figure 3



R = NHAc, NH<sub>2</sub>






Figure 4



R, R<sub>1</sub> = H, CH<sub>3</sub>

Figure 5



Compound	R
Epothilone A	H
Epothilone B	CH <sub>3</sub>

Figure 6




Figure 7

S.no.	R <sub>1</sub>	R <sub>2</sub>
1a	Me	H
1b	Me	COMe
1c	Ph	H
1d	Me	COOEt
1e	CH <sub>2</sub> COOEt	H
1f	COOEt	H

1








Figure 8


S.no.	R	R <sub>1</sub>	R <sub>2</sub>
2a	OMe	CH <sub>2</sub> CH <sub>2</sub> OMe	H
2b	OMe	CH <sub>2</sub> CH <sub>2</sub> OMe	Me
2c	OMe	CH <sub>2</sub> CH <sub>2</sub> OMe	CH <sub>2</sub> CH <sub>2</sub> OMe
2d	OMe	Me	CH <sub>2</sub> CH <sub>2</sub> OMe
2e	Br	CH <sub>2</sub> CH <sub>2</sub> OMe	H
2f	Br	CH <sub>2</sub> CH <sub>2</sub> OMe	Me
2g	Br	CH <sub>2</sub> CH <sub>2</sub> OMe	CH <sub>2</sub> CH <sub>2</sub> OMe
2h	Br	Me	CH <sub>2</sub> CH <sub>2</sub> OMe
2i	F	CH <sub>2</sub> CH <sub>2</sub> OMe	H
2j	F	CH <sub>2</sub> CH <sub>2</sub> OMe	Me
2k	F	CH <sub>2</sub> CH <sub>2</sub> OMe	CH <sub>2</sub> CH <sub>2</sub> OMe
2l	F	Me	CH <sub>2</sub> CH <sub>2</sub> OMe
2m	F	H	CH <sub>2</sub> CH <sub>2</sub> OMe
2n	H	H	CH <sub>2</sub> CH <sub>2</sub> OMe
2o	Br	H	CH <sub>2</sub> CH <sub>2</sub> OMe

2

Figure 9




S.no.	R	R <sub>1</sub>
3a	Cl	
3b	Cl	
3c	Cl	
3d	Cl	
3e	Cl	
3f	F	
3g	F	



3

Figure 10


S.no.	R <sub>1</sub>	R <sub>2</sub>
4a	H	3-OH
4b	H	4-F
4c	OEt	4-OH
4d	Me	4-F
4e	H	3-OPh
4f	OMe	4-F



4

Figure 11

S.no.	R
5a	H
5b	4-NO <sub>2</sub>
5c	4-CH <sub>3</sub>
5d	4-OCH <sub>3</sub>
5e	4-Br
5f	4-Cl



5

Figure 12






Figure 13

S.no.	X
7a	H
7b	Cl
7c	OCH <sub>3</sub>

7

Figure 14



S.no.	R	R
9a	p-Bromo	p-NO <sub>2</sub>
9b	p-Bromo	p-Bromo
9c	p-NO <sub>2</sub>	p-Bromo
9d	p-NO <sub>2</sub>	p-NO <sub>2</sub>
9e	p-Bromo	p-Chloro

9

Figure 15

S.no.	R	R
9a	p-Bromo	p-NO <sub>2</sub>
9b	p-Bromo	p-Bromo
9c	p-NO <sub>2</sub>	p-Bromo
9d	p-NO <sub>2</sub>	p-NO <sub>2</sub>
9e	p-Bromo	p-Chloro

**9**

Figure 16

S.no.	R	X
10a	Cl	CH <sub>3</sub>
10b	Cl	

**10**

Figure 17

S.no.	X	R <sub>1</sub>	R <sub>2</sub>	R <sub>3</sub>
11a	Cl	CH <sub>3</sub>	Cl	H
11b	Cl	Cl	Cl	Cl

**11**

S.no	Ar
12a	
12b	
12c	

**12**

Figure 18




Figure 19

S.no.	R	<p>14</p>
14a	4-F	
14b	4-Cl	
14c	3-CF <sub>3</sub>	
14d	4-Br	
14e	2-OMe	

Figure 20




Figure 21








S.no.	R	 16
16a		
16b		
16c		
16d		
16e		
16f		

Figure 22





Figure 23

S.no	R	R <sub>1</sub>	 <p style="text-align: center;">18</p>
18a	OCMe	4-MeC <sub>6</sub> H <sub>4</sub>	
18b	OCMe	4-OMeC <sub>6</sub> H <sub>4</sub>	
18c	OCOEt	4-OMeC <sub>6</sub> H <sub>4</sub>	


S.no	Ar	R <sub>1</sub>	 <p style="text-align: center;">19</p>
19a	4-OMeC <sub>6</sub> H <sub>4</sub>	Ph	
19b	2-Furyl	Ph	

Figure 24